FindTrial
Sign In

Randomized clinical trials comparing Lens extraction alone versus Phacoviscogonioplasty in the management of primary angle closure (PAC) and mild to moderate primary angle closure glaucoma with cataract

Randomized clinical trials comparing Lens extraction alone versus Phacoviscogonioplasty in the management of primary angle closure (PAC) and mild to moderate primary angle closure glaucoma with cataract

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100046296
Enrollment
Unknown
Registered
2021-05-12
Start date
2021-05-10
Completion date
Unknown
Last updated
2021-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Angle-Closure Glaucoma

Interventions

Control group:Phacoemulsification alone
Experimental group:Phacoviscogonioplasty

Sponsors

Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Chinese patients whose age>= 40 years old. 2.Newly diagnosed of PAC and PACG. 3.The Definition for Visual significant cataract 4.Informed consent.

Exclusion criteria

Exclusion criteria: 1.Unwilling or unable to give consent, unwilling to accept randomization, or unable to return for scheduled protocol visits; 2.Any condition precluding or presumed to preclude reliable visual fields, disc stereo photography; 3.Previous intraocular surgery (LPI is allowed); 4.Previous eye trauma resulting in documented damage to the drainage angle (such as angle recession); 5.For patients on warfarin, INR > 3.0 on preoperative examination; 6.Evidence of moderate non-proliferative diabetic retinopathy, neovascularization, or rubeosis iridis; 7.Chronic use of topical or systemic steroids; 8.Eyes with intumescent cataract (Phacomorphic glaucoma) or symmetric ACD greater than 0.3mm and eyes with lens dislocation or malignant glaucoma proved by UBM; 9.Monocular subjects (BCVA worse than 0.1 (6/60) Snellen in non-study eye); 10.Advanced glaucoma with severe paracentral or generalized VFD threatening fixation (advanced VFD defined as VFI >= –15 dB or C/D >=09); 11.Allergic to acetazolamide.

Design outcomes

Primary

MeasureTime frame
Intraocular pressure;anti-glaucoma medication;—

Countries

China

Contacts

Public ContactWang Ningli

Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University

alisawang0820@163.com+86 13511026669

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026